ACXP Share Price Performance
US$3.71
-3.88 (-51.09%)
81.5% undervalued intrinsic discount
US$20.00
Fair Value
Price US$3.71
AnalystLowTarget US$20.00
Fair ValueUS$20.00
Share Pricen/a
Acurx Pharmaceuticals, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
ACXP Community Narratives
AN
Fair Value US$20 81.5% undervalued intrinsic discount
Antibiotic Resistance Threats And Funding Risks Will Eventually Reward This Microbiome Sparing Platform
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Antibiotic Resistance Threats And Funding Risks Will Eventually Reward This Microbiome Sparing Platform
Catalysts About Acurx Pharmaceuticals Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing DNA polymerase IIIC inhibitor antibiotics such as ibezapolstat for serious Gram positive bacterial infections including C. diff.Read more
4
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$20
81.5% undervalued intrinsic discount
Fair Value
Profit Margin
10.89%
Future PE
21.45x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Antibiotic Resistance Threats And Funding Risks Will Eventually Reward This Microbiome Sparing Platform
Fair Value: US$20 81.5% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Acurx Pharmaceuticals, Inc. Key Details
About ACXP
- Founded
- 2017
- Employees
- 4
- CEO
- WebsiteView website
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
